Concepts (95)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| DNA, Viral | 6 | 2016 | 323 | 0.780 |
Why?
|
| Anal Canal | 3 | 2019 | 32 | 0.740 |
Why?
|
| AIDS Dementia Complex | 3 | 2017 | 116 | 0.690 |
Why?
|
| Anus Neoplasms | 3 | 2019 | 43 | 0.690 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2018 | 246 | 0.600 |
Why?
|
| Human papillomavirus 16 | 1 | 2018 | 37 | 0.570 |
Why?
|
| HIV Infections | 7 | 2018 | 2535 | 0.560 |
Why?
|
| Cognition Disorders | 3 | 2015 | 243 | 0.550 |
Why?
|
| Papillomavirus Infections | 2 | 2018 | 363 | 0.490 |
Why?
|
| Monocytes | 7 | 2019 | 275 | 0.470 |
Why?
|
| Viral Load | 4 | 2017 | 344 | 0.280 |
Why?
|
| Blood-Brain Barrier | 2 | 2019 | 167 | 0.270 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2021 | 209 | 0.250 |
Why?
|
| Precancerous Conditions | 2 | 2019 | 83 | 0.230 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2018 | 229 | 0.230 |
Why?
|
| Anti-HIV Agents | 3 | 2019 | 475 | 0.220 |
Why?
|
| Early Detection of Cancer | 2 | 2019 | 428 | 0.220 |
Why?
|
| Mass Screening | 2 | 2019 | 531 | 0.220 |
Why?
|
| Lymphoma, B-Cell | 1 | 2021 | 28 | 0.170 |
Why?
|
| Adult | 11 | 2021 | 13458 | 0.170 |
Why?
|
| HIV Seropositivity | 2 | 2019 | 196 | 0.170 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2018 | 22 | 0.150 |
Why?
|
| Viremia | 1 | 2018 | 44 | 0.150 |
Why?
|
| Galectins | 1 | 2018 | 29 | 0.150 |
Why?
|
| Antigens, CD | 1 | 2018 | 122 | 0.140 |
Why?
|
| Spectrum Analysis, Raman | 1 | 2019 | 94 | 0.140 |
Why?
|
| Receptors, Cell Surface | 1 | 2018 | 146 | 0.140 |
Why?
|
| Family Characteristics | 1 | 2019 | 124 | 0.140 |
Why?
|
| Humans | 15 | 2021 | 42163 | 0.140 |
Why?
|
| Central Nervous System | 1 | 2018 | 150 | 0.140 |
Why?
|
| Male | 11 | 2021 | 22779 | 0.130 |
Why?
|
| RNA, Viral | 1 | 2018 | 317 | 0.130 |
Why?
|
| Middle Aged | 6 | 2019 | 11819 | 0.130 |
Why?
|
| HIV-1 | 4 | 2019 | 747 | 0.130 |
Why?
|
| Female | 11 | 2021 | 24018 | 0.130 |
Why?
|
| Neuroprotective Agents | 1 | 2019 | 267 | 0.130 |
Why?
|
| Autopsy | 1 | 2016 | 46 | 0.130 |
Why?
|
| Cytokines | 2 | 2017 | 661 | 0.120 |
Why?
|
| Anti-Retroviral Agents | 1 | 2016 | 158 | 0.120 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2015 | 10 | 0.120 |
Why?
|
| Algorithms | 1 | 2018 | 508 | 0.120 |
Why?
|
| Burkitt Lymphoma | 1 | 2015 | 25 | 0.120 |
Why?
|
| Models, Biological | 1 | 2018 | 711 | 0.110 |
Why?
|
| Cognition | 2 | 2018 | 458 | 0.110 |
Why?
|
| Cyclohexanes | 1 | 2014 | 30 | 0.110 |
Why?
|
| Cell Movement | 1 | 2018 | 640 | 0.110 |
Why?
|
| Atrophy | 1 | 2014 | 51 | 0.110 |
Why?
|
| Sampling Studies | 1 | 2013 | 64 | 0.100 |
Why?
|
| Triazoles | 1 | 2014 | 100 | 0.100 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 683 | 0.100 |
Why?
|
| Lymphocytes | 1 | 2013 | 124 | 0.100 |
Why?
|
| Homosexuality, Male | 1 | 2018 | 483 | 0.100 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2014 | 225 | 0.100 |
Why?
|
| Papillomaviridae | 1 | 2012 | 136 | 0.090 |
Why?
|
| Brain | 2 | 2014 | 1452 | 0.080 |
Why?
|
| Puerto Rico | 1 | 2013 | 1376 | 0.080 |
Why?
|
| Cohort Studies | 1 | 2013 | 1729 | 0.080 |
Why?
|
| Hawaii | 1 | 2013 | 2004 | 0.070 |
Why?
|
| Neuropsychological Tests | 2 | 2018 | 281 | 0.060 |
Why?
|
| Thailand | 2 | 2015 | 51 | 0.060 |
Why?
|
| Prospective Studies | 3 | 2014 | 1574 | 0.060 |
Why?
|
| Child, Preschool | 2 | 2021 | 1516 | 0.050 |
Why?
|
| Anthracyclines | 1 | 2021 | 9 | 0.040 |
Why?
|
| Adolescent | 3 | 2021 | 5950 | 0.040 |
Why?
|
| Survival Rate | 1 | 2021 | 353 | 0.040 |
Why?
|
| Child | 2 | 2021 | 3381 | 0.040 |
Why?
|
| Neopterin | 1 | 2018 | 13 | 0.040 |
Why?
|
| Prognosis | 1 | 2021 | 850 | 0.040 |
Why?
|
| Biopsy | 1 | 2019 | 176 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 1051 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 1112 | 0.030 |
Why?
|
| Young Adult | 2 | 2021 | 4936 | 0.030 |
Why?
|
| Incidence | 1 | 2019 | 1054 | 0.030 |
Why?
|
| Receptors, CCR2 | 1 | 2015 | 28 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2015 | 15 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 1139 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2018 | 1266 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2014 | 68 | 0.030 |
Why?
|
| Receptors, IgG | 1 | 2014 | 53 | 0.030 |
Why?
|
| Receptors, CCR5 | 1 | 2014 | 64 | 0.030 |
Why?
|
| Risk Factors | 2 | 2013 | 3942 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2018 | 1617 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2015 | 411 | 0.030 |
Why?
|
| Disease Management | 1 | 2014 | 68 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2018 | 467 | 0.030 |
Why?
|
| ROC Curve | 1 | 2013 | 157 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1020 | 0.020 |
Why?
|
| HIV | 1 | 2013 | 100 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2015 | 733 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2013 | 487 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2013 | 203 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 638 | 0.020 |
Why?
|
| Gene Expression | 1 | 2014 | 692 | 0.020 |
Why?
|
| Aged | 2 | 2014 | 7982 | 0.020 |
Why?
|
| Genotype | 1 | 2012 | 796 | 0.020 |
Why?
|
Agsalda-Garcia's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(95)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(12)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_